Broadfin Capital’s NEVRO CORP. NVRO Stock Holding History

Broadfin Capital’s Portfolio NVRO Stock Details NVRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-150,510	Closed	-$12.9M	–	48
2019 Q3	$12.9M	Sell	150,510 -337,755	-69%	-$25.6M	2.39%	13
2019 Q2	$31.7M	Sell	488,265 -134,350	-22%	-$8.37M	6.89%	3
2019 Q1	$38.9M	Sell	622,615 -121,800	-16%	-$5.73M	8.04%	2
2018 Q4	$28.9M	Buy	+744,415	New	+$33.1M	3.81%	5
2017 Q1	–	Sell	-43,281	Closed	-$3.15M	–	66
2016 Q4	$3.15M	Sell	43,281 -7,274	-14%	-$623K	0.35%	53
2016 Q3	$5.28M	Sell	50,555 -341,800	-87%	-$30.9M	0.47%	51
2016 Q2	$28.9M	Sell	392,355 -275,552	-41%	-$18.7M	2.81%	9
2016 Q1	$37.6M	Sell	667,907 -533,573	-44%	-$31.5M	3.63%	7
2015 Q4	$81.1M	Sell	1,201,480 -405,605	-25%	-$21.7M	4.99%	4
2015 Q3	$74.6M	Buy	1,607,085 +1,187,526	+283%	+$57.5M	4.15%	3
2015 Q2	$22.6M	Buy	+419,559	New	+$21.4M	1.21%	19

Other funds holding NVRO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Broadfin Capital's NVRO Position: Q4 2019 in Review

Broadfin Capital sold out of NEVRO CORP. (NVRO) in Q4 2019, closing a stake of 150,510 shares — an estimated $12.9M sold.

Broadfin Capital first reported a position in NVRO in Q2 2015 and held it in 11 quarters. The position peaked at $81.1M in Q4 2015. 191 funds tracked by Wall St. Rank hold NVRO as of Q4 2019.

Broadfin Capital reported no remaining NEVRO CORP. position as of Q4 2019 after selling out during the quarter.
Broadfin Capital sold 150,510 NEVRO CORP. shares in Q4 2019, an estimated $12.9M.
Broadfin Capital first reported a position in NEVRO CORP. in Q2 2015 and held it in 11 quarters.
Broadfin Capital's NEVRO CORP. position peaked at $81.1M in Q4 2015.
191 funds tracked by Wall St. Rank held NEVRO CORP. as of Q4 2019.

Based on Broadfin Capital's 13F filing for Q4 2019, filed 14 Feb 2020.